Keyword: Abilify

Though she has spent most of her career in oncology, Deborah Dunsire, M.D., says she doesn't plan to expand Lundbeck outside of neuroscience.

What's notable about the 10 best-selling drugs over the past 25 years? Here's a hint: Today's king is passing, and the next has a long life ahead.

Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as companies increasingly focus on rare disease meds.

U.S. government watchdogs plan to probe the FDA's orphan drug policies after Marathon's high-profile pricing scandal.

Sen. Chuck Grassley is investigating whether “unanticipated uses” of the Orphan Drug Act have helped jack up U.S. drug prices.

Years after wrapping up Abilfy marketing allegations with the U.S. Justice Department, Bristol-Myers Squibb agreed to pay $19.5 million to settle similar claims at the state level.

Otsuka and Lundbeck are setting out for a label expansion for Abilify Maintena in bipolar I disorder.

As sales of its star immuno-oncology med Opdivo fell short for the quarter, Bristol-Myers Squibb unveiled an operational rejig spanning R&D and manufacturing.

Lundbeck’s focus on the U.S. is paying off. And it’s a good thing, too. While revenue in its native Europe slid by one-fourth in the first half of this year, U.S. sales drove the Danish drugmaker to 5% sales growth overall.